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Abstract 
The dynamics of active human Cytomegalovirus (HCMV) infection was 
monitored by competitive nucleic acid sequence-based amplification (NASBA) 
assays for quantification of IE1 (UL123) and pp67 (UL65) mRNA expression levels 
in the blood of patients after lung transplantation. RNA was isolated from 339 
samples of 13 lung transplant recipients and analyzed by the quantitative IE1 and 
pp67 NASBA in parallel with pp65-antigenemia and serology. Rapid increases in 
IE1 RNA exceeding 104 copies per 100 l of blood were associated with active 
infection, whereas lower levels were suggestive for abortive, subclinical viral 
activity. Any positive value for pp67 RNA was indicative for active infection, and 
quantification of pp67 mRNA did not give additional diagnostic information. The 
onset of IE1-positive NASBA preceded pp67 NASBA and was earlier than the pp65-
antigenemia assay, confirming previous studies with qualitative NASBA. Effective 
antiviral treatment was reflected by a rapid disappearance of pp67 mRNA, 
whereas IE1 mRNA remained detectable for longer periods. Quantification of IE1 
might be relevant to monitor progression of HCMV infection but should be 
validated in prospective studies. 
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Introduction 
Human Cytomegalovirus (HCMV) is ubiquitous in humans, and primary 
infection generally occurs without clinical symptoms. However, in AIDS patients, 
newborns, transplant recipients and other immunocompromised individuals, 
HCMV can cause severe disease (5). In order to prevent development of HCMV-
related disease in these patients, well-timed pre-emptive initiation of antiviral 
therapy is of importance, guided by an early and accurate diagnosis. Especially in 
transplant recipients, frequent monitoring for HCMV infection is essential for 
appropriate patient management, since symptoms of infection and rejection of 
the transplanted organ may be similar, whereas the therapeutic approaches are 
opposite (12,23,28). The development of accurate diagnostic approaches has 
been ongoing for many years, aiming to solve several problems: early detection 
of aberrant virus activity and discrimination between abortive, subclinical 
infection and clinically relevant viral activity leading to HCMV disease. Currently, 
antigenemia monitoring is increasingly used to initiate antiviral therapy 
(22,25,26) and may be confirmed by shell-vial culture (13), whereas nucleic acid 
(DNA and RNA) diagnostics are still being validated for their diagnostic relevance 
in many institutes (3). For the specific detection of HCMV RNA transcripts in 
patient materials, nucleic acid sequence-based amplification (NASBA) was 
developed (1). In contrast to HCMV DNA, which may be present in circulating 
leukocytes as a stable and inert molecule (17), the presence of HCMV specific 
mRNA directly reflects viral biological activity. Systemic spread of HCMV via 
productively infected circulating blood leukocytes is a hallmark of disseminating 
infection, closely linked to development of HCMV disease, and should be limited 
at an early stage (24). Studies using reverse transcription-PCR for detection of 
mRNA have indicated that late viral transcripts reflect active HCMV replication in 
contrast to immediate-early transcripts, which lack specificity for prediction of 
HCMV disease (11,16,18,20). However, reverse transcription-PCR detecting late 
mRNA as pp150 (18) and UL18 (14) was only positive in the peak of infection. The 
low sensitivity may be overcome by using a abundantly expressed mRNA such as 
pp67 (6). 
In recent studies, qualitative NASBA for the detection of late-stage pp67 
(UL65) RNA, encoding a structural tegument protein, has proved to be a sensitive 
and specific assay for monitoring active systemic HCMV infection in solid 
transplant recipients (1,8). From the study of Blok et al. (1) it was concluded 
that NASBA for late pp67 mRNA is more sensitive than the antigenemia assay for 
the detection of HCMV infection in renal allograft recipients. Furthermore, pp67 
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NASBA proved useful for monitoring progression of HCMV infection in heart, lung 
and bone marrow patients and to determine the effect of antiviral therapy with 
results comparable to those of the antigenemia and DNA-emia assays (8). 
However, in high-risk bone marrow transplant recipients, the pp67 NASBA showed 
a mean delay of 2 days before becoming positive in comparison to antigenemia 
results.  
In order to identify active HCMV infection at an earlier stage, an NASBA 
assay was developed for qualitative detection of mRNA encoded by the 
immediate early gene UL123 (IE1) (2,9). IE1 NASBA proved to be highly sensitive, 
detecting the onset of both primary and secondary Cytomegalovirus infection 
significantly earlier than cell culture, antigenemia, and pp67 NASBA in renal, 
liver, heart, and lung transplant recipients (2,21). Also in bone marrow 
transplant patients IE1 NASBA was significantly earlier than pp67 NASBA, pp65-
antigenemia and DNA-emia (9). The IE1 NASBA results indicated that IE1 mRNA 
detection might provide a useful parameter for starting preemptive antiviral 
treatment in high-risk patients. However, following anti-viral therapy, HCMV IE1 
mRNA may still be expressed, since current antiviral drugs selectively inhibit viral 
DNA replication and thereby late mRNA synthesis, but may leave earlier stages of 
viral gene expression relatively unaffected. Therefore, the merely qualitative IE1 
NASBA may not be ideal for monitoring HCMV activity. The high sensitivity and 
associated lower specificity for predicting symptomatic HCMV infection of 
qualitative IE1 mRNA monitoring was further indicated in previous studies using 
reverse transcription-PCR (16,18,20). This was confirmed by a study of Oldenburg 
evaluating IE1, 2.7 (early mRNA) and pp67 gene expression by NASBA in thoracic 
organ transplant recipients (21). In this study, IE1 mRNA was detected in a 
significant number of cases with subclinical HCMV infection that did not require 
antiviral treatment. The early detection of IE1 mRNA in certain samples might by 
related to HCMV-positive blood transfusion. A quantitative NASBA for measuring 
IE1 RNA levels could be more informative for accurate monitoring of relevant 
HCMV activity potentially leading to disease. Currently no data are available on 
the quantity and kinetics of symptomatic and subclinical HCMV RNA expression in 
blood during active infection.  
To analyze in more detail the in vivo dynamics of mRNA expression in the 
circulation of HCMV-infected patients and to determine their relevance for 
predicting the progression of subclinical infection to disease, quantitative 
versions of the HCMV-specific IE1 and pp67 NASBA assays were developed. 
Quantification was performed by incorporating a competitively coamplified RNA 
construct with identical length and sequence as the wild-type (wt) RNA, except 
for 20 randomized nucleic acids, allowing its specific detection. HCMV RNA 
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expression levels were determined in weekly samples of unfractionated whole 
blood in control patients and in lung transplant recipients with primary and 
secondary HCMV infections by quantitative IE1 and pp67 NASBA and compared to 
pp65 antigenemia and serology in simultaneously obtained samples. 
Materials and Methods 
Clinical samples 
Heparinized whole-blood samples and serum specimens of patients 
transplanted between 1997 and 1998 were collected weekly following 
transplantation during admission and and at each patient visit thereafter. One ml 
blood was mixed with 9 ml of NASBA lysis buffer (5 M guanidine isothiocyanate, 
0.1 M Tris [pH 6.4], 20 mM EDTA [pH 8.0], 1.2% [wt/vol] and stored at -80°C. 
Serum samples were stored at -20°C. 
Patients 
In the period from 1997 to 1998, 17 patients received a lung transplant, of 
which 4 patients died within 3 months. Of the 13 lung transplant patients 
studied, 2 patients were HCMV seronegative and received a seronegative 
transplant, 3 patients were seronegative and received an organ from a HCMV 
seropositive donor, and 8 patients were already seropositive, of which six 
transplant recipients received an HCMV-positive and 2 received a HCMV- negative 
transplant. The two negative donor/recipient matches did not show any signs or 
symptoms of HCMV infection. Of the primary infected patients, all three had an 
active HCMV infection that required antiviral therapy. Of the 8 seropositive 
patients receiving a positive transplant, 5 developed an active HCMV infection, 
whereas the two seropositive patients receiving a negative transplant did not 
have a reactivation of HCMV.  
Treatment 
All patients received standard immunosuppressive treatment with rabbit 
anti-thymocyte globulin (3 mg/kg, 2-5 times postoperatively, Thymoglobulin®, 
Merieux, France), azathioprine (1.5-3 mg/kg/day), cyclosporine A (dose adjusted 
to whole blood trough levels of 400 g/l within 3 weeks tapering to levels of 150 
g/l), prednisolone (three times 125 mg the first day, 0.2 mg/kg/day from day 2 
to third month and 0.1 mg/kg/day thereafter), pneumocystis carinii prophylaxis 
with cotrimaxozole (960 mg on alternate days), and acyclovir (200 mg four times 
a day for 6 months). Acute rejection was treated with pulse therapy of 
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methylprednisolone (500-1000 mg intravenously daily for 3 days). Recurrent 
rejection was treated by replacement of cyclosporine by FK506 (Prograft, 
Fujisawa, Japan) and subsequently from azathioprine to methylmycophenolate 
mofetil (cellcept, Roche, Switserland). Cytomegalovirus-related disease was 
treated with intravenous ganciclovir (Cymevene, Roche) or Foscarnet (Foscavir) 
until pp65-antigenemia levels dropped below the limit of detection (25). One 
patient received hyperimmune globulin, (Megalotect; Biotest, Dreieich, 
Germany) in addition to ganciclovir and foscarnet. 
Antigenemia and serology 
HCMV antigenemia was determined as described previously (25,26). In short, 
peripheral blood leukocytes were isolated by dextran sedimentation and 
cytocentrifuged onto glass slides. These slides were air dried, fixed with 
formaldehyde, permeabilized with Nonidet p-40, and stained with a mixture of 
monoclonal antibodies C10 and C11, directed against the pp65 protein (Biotest) 
using an indirect immunoperoxidase technique. The total number of HCMV 
antigen-positive cells was scored and expressed per 50,000 leukocytes analyzed. 
Immunoglobulin M (IgM) and IgG antibodies against HCMV were determined by a 
semi-quantitative enzyme-linked immunosorbent assay (ELISA) using alkaline 
glycine-extracted HCMV antigens obtained from HCMV AD169-infected fetal 
fibroblasts and in parallel on an extract of mock-infected fibroblasts (27). Serum 
samples were added in serial twofold dilutions starting with 1:100, and bound 
HCMV-specific antibody was detected with a peroxidase-labeled sheep antibody 
against human immunogloblulins. The amount of antibody present in the patient 
serum was calculated relative to that of a standard serum which was included in 
each plate. Results were quantitatively expressed as a percentage of the 
standard sera containing high levels of IgM and IgG antibodies, which were set at 
100 U. 
Virus and cell culture 
Human fetal lung fibroblasts (H LF) w ere cultured in a 1:1 m ixture of H am ‟s 
F12 and D ulbecco‟s m odified Eagle m edium  supplem ented w ith 10%  fetal bovine 
serum (Hyclone, Logan, Utah). HLF cells were infected with cell-free HCMV virus 
at 0.01 PFU per cell during 1 hour, and medium with 10% serum was refreshed, 
followed by incubation for 3 days. Infected cells were washed twice with 
phosphate-buffered salins (PBS) and harvested by trypsinization, followed by 
centrifugation at 1,000 x g. The cell pellet was washed with PBS and dissolved in 
NASBA lysis buffer.  
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Nucleic acid isolation 
Total nucleic acid was isolated from 1 ml whole blood in NASBA lysis buffer 
using a solid-phase silica extraction technology essentially as described by Boom 
et al (4). Before isolation, the internal calibrator RNA (Q RNA) was spiked into 
the sample (104 copies of IE1 and 2x105 copies of pp67 Q RNA per ml sample). 
The Q RNA allows accurate and controlled quantification of the amplified target 
RNA. The Q RNA was identical to the sequence of amplified wt RNA except for 
the region complementary to the enhanced chemiluminescence (ECL) detection 
probes (Greijer et al., submitted for publication). The extracted nucleic acids 
were eluted into 50 l of elution buffer and stored at –70°C. 
Qt NASBA 
The quantitative (Qt) NASBA amplification reaction was performed on 5 l of 
nucleic acid eluate using with two primers, which were designed to amplify a 
part of the mRNA encoded by UL65 and UL123 exon 4 (1,2). The IE1 and pp67 
NASBA was carried out essentially as described by Greijer et al. (submitted). 
Briefly, wt and Q RNA were coamplified using a T7 promoter containing primer 
and a reverse primer. The amplification was initiated by an enzyme mix 
containing avian myeloblastosis virus-reverse transcriptase (Seikagaku, Rockville, 
Md), RNase H, and T7 RNA polymerase (Pharmacia, Upsala, Sweden) (15). 
Amplification products were detected by electrochemiluminescence system, 
using capture probes coupled to magnetic beads and wt- and Q-specific 
ruthenium-labeled oligonucleotide detection probes by the NASBA QR system 
(Organon Teknika, Boxtel, The Netherlands). The number of wt RNA molecules 
per 100 µl of blood was calculated by a formula based upon a linear regression of 
the ratio between the wt signal and the calibrator signal (7). For determination 
of the parameters in the formula, three RNA concentrations of IE1 and pp67 in 
vitro RNA (103, 104 and 106 copies per ml blood in lysis buffer) were tested 
sixfold. From these dose-effect curves, correction factors a and b were 
estimated, which were used to calculate wt RNA and Q RNA concentration 
according to the formula; log Wtconc = 1/a  (log WTECL- log QECL + log Qconc) –b/a.  
Results 
Performance of the IE1 Qt and pp67 Qt NASBA 
The analytical performance of the IE1 and pp67 Qt NASBA is described 
elsewhere (Greijer et al, submitted). The sensitivity of Qt NASBA was similar to 
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the qualitative NASBA described earlier, which had a threshold level of 70 copies 
of IE1 RNA (9) and 100 copies of pp67 RNA. For analyzing the influence of whole 
blood on the quantification of HCMV RNA, HLF were infected with HCMV at 0.01 
PFU per cell for 72 hours cells followed by homogenization with NASBA lysis 
buffer. The homogenate was diluted to a range of 0.01 to 100 HCMV infected cell 
equivalents per ml of lysis buffer or spiked at identical concentrations in whole 
blood from healthy individuals. The sensitivity for pp67 Qt NASBA in both lysis 
buffer and blood was 0.01 HCMV- infected cell equivalent per ml (Fig. 1). The IE1 
NASBA is sensitive to 0.1 cell equivalent per ml due to the 10-fold-lower 
expression level of IE1 mRNA in infected HLF cells (Greijer et al., submitted), 
confirming previous findings of Davis et al. (6).  
Figure 1: Characterization of IE1 and pp67 Qt NASBA in fibroblasts infected with 
HCMV at multiplicity of 0.01 in NASBA lysis buffer (shaded bars) compared to 
cells in a background of 100 l of blood from healthy donors in NASBA lysis 
buffer (solid bars). 
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The quantification of cells spiked in both lysis buffer and blood was linear 
over a range of 0.1 to 100 cell equivalents, which is equivalent to a range of 103 
to 106 RNA copies per ml (Greijer et al submitted). 
Detection of IE1 and pp67 mRNA in control groups 
To determine the clinical relevance of IE1 and pp67 Qt NASBA assays, whole 
blood samples of healthy individuals were analyzed. The IE1 Qt NASBA did not 
give any positive results for 144 healthy individuals tested. However, the pp67 Qt 
NASBA showed two weakly positive results among 144 healthy individuals. Since 
these results were obtained from seronegative individuals, these low positive 
values were considered to be due to a contamination. From two HCMV-
seronegative transplant recipients receiving an allograft from a seronegative 
donor, 25 and 28 subsequent samples were analyzed respectively, over a period 
of 36 and 60 weeks post transplantation. Neither IE1 nor pp67 Qt NASBA showed 
any positive result. 
Monitoring of IE1 and pp67 RNA during HCMV infection 
For routine diagnosis of HCMV infection, the pp65-antigenemia assay was 
performed in a standardized method as described by The (The 98). Results of the 
pp65-antigenemia were used as an indication to start and terminate antiviral 
therapy. The IE1 and pp67 Qt NASBA assays were performed retrospectively on 
samples collected simultaneously with routine pp65-antigenemia testing. Results 
of pp65-antigenemia, IE1 and pp67 Qt NASBA assays were compared (Table 1). 
Patients were grouped by primary and secondary infection. Of the 292 blood 
samples tested, 130 samples (45%) were pp65-antigenemia positive, whereas 188 
(65.7%) were positive for IE1 Qt NASBA and 60 (21.0%) were positive for pp67 Qt 
NASBA. 
Most blood samples positive for pp65 antigenemia in patients with a primary 
or secondary HCMV infection had detectable levels of IE1 RNA (89.2%), whereas 
pp67 RNA was present less frequently (36.9%), especially in patients with a 
secondary HCMV infection (21.5%). However, when clinically relevant levels of 
pp65 antigenemia were detected (>10 pp65-positive cells per 50,000 tested), a 
higher number of patients with secondary HCMV were also positive for pp67 
mRNA (54.5%). Of 80 blood samples with negative results for pp65 antigenemia, 
detectable levels of IE1 mRNA were found in 41 samples (51.9%) and pp67 mRNA 
in 7 samples (8.9%). Positive pp67 Qt NASBA results with negative pp65 
antigenemia were all located in periods after the first peak of infection, where 
pp65 antigenemia results fluctuated between low positive and negative. For 
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further interpretation, the time to the first positive IE1 and pp67 Qt NASBA 
results after transplantation was analyzed in more detail.  





No. (%) of test samples  
IE1 Qt NASBA 
Positive      Negative 
pp67 Qt NASBA 
Positive       Negative 
Primary Positive 51  47 (92.2)  4 (7.80)  31 (60.8)  20 (39.2) 
 Negative 26  18 (69.2)  8 (44.4)  6 (23.1)  20 (76.9) 
 No result 11  2 (18.2)  9 (81.8)  0 (0)  11 (100) 
Secondary Positive 79  69 (87.3)  10 (12.7)  17 (21.5)  62 (78.5) 
 >10b 11  11 (100)  0 (0)  6 (54.5)  5 (45.5) 
 Negative 53  23 (43.4)  30 (56.6)  1 (1.89)  52 (65.8) 
 No result 66  29 (43.9)  37 (56.1)  5 (7.58)  61 (92.4) 
a Sam ples w ith „no result‟for antigenem ia are derived from  patients w ho had tw o 
successive negative antigenemia results, after which antigenemia was not determined 
again. 
b Clinically significant threshold values. 
 
Time to detection of HCMV infection 
In lung transplant patients with a primary infection, the first repeated pp65 
antigenemia positive result was used to initiate antiviral treatment. The timing 
of the first positive result by the IE1 and pp67 Qt NASBA assays was determined 
relative to the pp65 antigenemia assay during the early phase of infection. The 
results are given in Table 2. In patients with a primary HCMV infection, the onset 
of infection could be detected at the same time (3.4 weeks after transplantation) 
by pp65 antigenemia and IE1 Qt NASBA. Late pp67 mRNA was detected with a 5-
day delay compared to pp65 antigenemia and IE1 Qt NASBA. In patients with a 
secondary HCMV infection, pp65 antigenemia became positive at a mean 3.6 
weeks after transplantation. In two patients, the IE1 mRNA was detected 7 and 
10 days earlier than pp65 antigenemia, whereas in the other patients, both 
assays became positive simultaneously. pp67 RNA was detected with a delay of 
1.5 weeks compared to pp65 antigenemia. In this comparison, pp65 antigenemia 
results of more than one positive cell were used, which is considerably below the 
clinical level relevant for secondary infection. A patient with a secondary 
infection received antiviral therapy only where these were more than 10 pp65 
positive cells in the antigenemia assay or when clinical symptoms indicated 
active HCMV infection. Using the latter as criterion for the eight patients with a 
secondary infection, three patients had a positive result for pp67 mRNA. These 
patients already had high levels of pp65 antigenemia at the first available 
sample, and both IE1 and pp67 Qt NASBA were positive at the first tested sample. 
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Table 2: Time to first HCMV detection in blood of patients with a primary and 
secondary infection in comparison with the antigenemia assay. 
Infection HCMV assay No. of patients Mean time post transplantation 
(wk) of first HCMV appearance 
(first result– last result) 
Primary Antigenemia 3 3.4 (1.7-4.4) 
 IE1 Qt NASBA 3 3.4 (1.7-4.4) 
 pp67 Qt NASBA 3 4.1 (2.7-5.4) 
Secondary Antigenemia 5 3.6 (2.1-6.0) 
 IE1 Qt NASBA 7 3.3 (1.6-6.0) 
 pp67 Qt NASBA 5 5.8 (3.3-8.0) 
 
Quantification of HCMV IE1 and pp67 mRNA levels in transplant 
recipients 
In order to define the clinical relevance of HCMV RNA quantification, the 
levels of mRNA encoded by the IE1 and UL65 gene were compared to the level of 
pp65 antigenemia. For this purpose, pp65 antigenemia results were divided into 
negative and positive pp65 antigenemia and clinical relevant numbers of pp65-
positive cells (Table 3). The mean level of expression of IE1 was log 5.3 RNA 
copies per 100 l of blood. In patients with a primary infection, mean IE1 
expression levels rose 19-fold to log 6.6 RNA copies per 100 l of blood, 
paralleled by antigenemia levels exceeding 10 cells per 50,000 
polymorphonuclear leukocytes, whereas in patients with a secondary infection 
IE1 RNA levels did not exceed log 5.8 copies of IE1 RNA per 100 l of blood. 
Quantification of pp67 RNA shows an increase in the number of RNA copies with 
the number of pp65-positive cells. The overall mean level of pp67 RNA molecules 
was log 4.5 and the maximum number of RNA copies was log 5.6 per 100 l of 
blood. 
The comparison of IE1 and pp67 RNA quantification relative to the number 
of pp65-positive cells in the pp65 antigenemia assay of the individual blood 
samples is shown in Fig. 2. The level of IE1 RNA expression correlated with the 
level of the antigenemia (Fig. 2A), with 0 to 103 RNA copies per 100 l of blood 
being associated with negative antigenemia results. The level of pp67 RNA also 
showed correlation with increasing antigenemia levels, although much less 
stringent (Fig. 2B). 
In the current routine diagnostic approach, the course of HCMV infection in 
lung transplant recipients is reflected by the number of pp65-positive cells in the 
antigenemia assay. In order to acquire additional information on the progression 
of HCMV infection, the kinetics of IE1 and pp67 mRNA expression in blood were 
analyzed. The antigenemia, IE1 and pp67 mRNA levels of four representative 
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patients are presented in Fig. 3. For evaluation of the immune response, the 
levels of HCMV-specific IgM and IgG antibodies are presented as well. Fig. 3A and 
B represent two lung transplant recipients with a primary infection. In Fig. 3C 
and D represent two patients with a secondary HCMV infection. 
Table 3: Comparison of RNA levels with antigenemia results in 11 transplant 
recipients (153 SAMPLES) with a primary and secondary HCMV infection 
Infection Antigenemia 
(No. of positive cells) 
IE1 Qt NASBA pp67 Qt NASBA 
No. Positives RNA copies  
(log) 
No. positive RNA copies 
(log) 
Primary 0 18 3.89 6 4.12 
 1 9 3.97 2 2.85 
 2-10 13 4.77 7 4.20 
 >10 23 6.04 22 4.71 
Secondary 0 24 3.55 1 0.71 
 1 20 4.21 3 3.32 
 2-10 35 4.58 8 4.04 
 >10 11 4.66 6 4.62 
 
Kinetics of IE1 and pp67 mRNA levels in blood of patients with 
HCMV infection 
Patient 1 was seronegative and received a positive lung transplant. In order 
to prevent acute rejection, the patient was treated four times with 
methylprednisolone. The onset of HCMV infection was detected by antigenemia 
at 12 days after transplantation. At the same moment, IE1 Qt NASBA became 
positive, whereas the pp67 Qt NASBA became positive at 19 days. Three periods 
of active infection were seen. During the second and third peak of infection, the 
number of positive cells in the antigenemia assay increased considerably, to a 
maximum of 640 positive cells. Therapy with ganciclovir was successful at first 
but proved ineffective in the second period, and was therefore replaced by 
foscarnet. Sequencing of the viral DNA isolated from samples at week 24 and 25 
revealed a C T (Ala Val) mutation at codon 594 of the UL94 gene, known to 
cause ganciclovir resistance. 
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Figure 2: Levels of pp65-positive cells in the antigenemia assay compared with 
levels of IE1 and pp67 RNA levels determined by Qt NASBA in lung transplant 
patients with primary ( ) and secondary (○ ) HCMV infection. 
 
 
Due to adverse side effects, foscarnet treatment was ended 15 weeks after 
transplantation, and ganciclovir in combination with Megalotect was given until 
the antigenemia levels had decreased significantly. Fig. 3A clearly shows that at 
the initial phases of viral activity, the dynamics of IE1 and pp67 RNA expression 
were similar to the antigenemia. However, IE1 RNA levels remained positive  
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Figure 3: Course of HCMV infection in four representative patients by serology, 
pp65-antigenemia, and IE1 and pp67 Qt NASBA assays.  
(A and B) Patients with primary HCMV infection.  
(C and D) patients with secondary HCMV infection. 
GCV, ganciclovir; PFA, foscarnet; ACV, acyclovir. Arrows, rejection treatment 
  
 
during the period of foscarnet therapy, while antigenemia and pp67 Qt NASBA 
were negative. The pp67 Qt NASBA detected HCMV infection in all three periods 
of active infection 1 week later than IE1 NASBA. During therapy with foscarnet, 
pp67 RNA and antigenemia were negative. Significantly decreased pp67 RNA 
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levels indicated the final success of therapy at 14 weeks, which was before 
antigenemia and IE1 RNA. 
Patient 2 had a primary HCMV infection and subsequently developed a 
primary Epstein-Barr virus (EBV) infection. Antirejection therapy was given six 
times. The acyclovir treatment for EBV is also shown in figure 3B. After 4.4 
weeks, increasing antigenemia showed the first signs of HCMV infection. 
Simultaneously, IE1 Qt NASBA became positive, and IE1 RNA levels corresponded 
with the antigenemia levels. pp67 RNA was detected with a delay of 7 days and 
weeks later in the second peak of infection. In contrast to patient 1, the levels of 
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was 3 IE1 RNA expression were substantially lower. Furthermore, IE1 RNA 
reappeared each time a rejection treatment was given, while the antigenemia 
and the pp67 Qt NASBA assay remained negative. The sole presence of IE1 RNA 
indicated restricted activity of the HCMV infection, since clinical symptoms of 
HCMV infection were absent (subclinical infection). 
An example of the kinetics of IE1 and pp67 RNA expression in a HCMV-
seropositive transplant patient is shown in figure 3C. Patient 3 had seven 
rejection treatments and four periods of HCMV activity, with short antiviral 
treatments with ganciclovir. Although antigenemia did not exceed 20 pp65-
positive cells, ganciclovir was given in order to prevent progression of the 
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infection during antirejection therapies. The onset of HCMV infection was 
defined at 18 days after transplantation. Prior to this period, samples were not 
available for analysis of IE1 and pp67 mRNA. In the second peak of infection, 
antigenemia and IE1 Qt NASBA were positive simultaneously at 6 weeks, whereas 
pp67 Qt NASBA was positive with a 2-week delay. Levels of IE1 RNA remained 
elevated during periods of positive antigenemia, and when antigenemia and pp67 
became negative, IE1 RNA was still detectable, although at lower levels. The 
pp67 Qt NASBA showed positive results only in the highest peaks of infection.  
Patient 4 was seropositive and received an HCMV positive organ. A 
secondary infection was diagnosed at 12 days after transplantation, and 
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antigenemia was detectable for 1 week (Fig. 3D). The first positive result by 
antigenemia could not be tested by NASBA, but the second sample was positive 
for both antigenemia and IE1 Qt NASBA. The pp67 Qt NASBA did not show any 
positive results in the period of elevated IE1 RNA level. The low positive 
antigenemia did not necessitate antiviral therapy, but in combination with 
rejection therapy, ganciclovir was given prophylactically. 
Discussion 
Active HCMV infection remains a significant problem in the transplantation 
population. Control of HCMV activity in solid organ transplant recipients is of 
importance for preventing HCMV disease and improving overall clinical 
performance. The main implication of our study is that quantification of pp67 
RNA does not provide additional information compared to the previously 
described qualitative pp67 RNA detection, whereas quantification of IE1 RNA 
more directly reflects the dynamics of HCMV infection. Furthermore, the rapid 
increases to high levels of IE1 RNA are associated with progression to disease. 
Previous studies have shown that qualitative monitoring for the presence of 
HCMV RNA by either reverse transcription-PCR or NASBA could provide a useful 
diagnostic approach directly reflecting active viral gene expression in circulating 
HCMV-infected cells (11,16,18,20). In recent years, monitoring for the presence 
of pp67 and IE1 mRNA by NASBA was introduced to provide a new approach for 
early detection of systemic active infection. The pp67 NASBA has a relatively 
limited sensitivity, since it detects only the late productive stage of infection. 
However, pp67 mRNA monitoring may provide timely diagnosis for initiation of 
preemptive therapy (1,8,21). IE1 NASBA, although providing very early positive 
results, may lack specificity for predicting disease (2,9,21).  
In order to monitor patients more closely and analyze the kinetics of 
expression of IE1 and pp67 in more detail, quantitative competitive pp67 and IE1 
Qt NASBA assays were developed. In healthy control blood donors and HCMV-
seronegative patients receiving an HCMV-seronegative organ, IE1 and pp67 mRNA 
could not be detected by the Qt NASBA assays at any time during follow-up. Of 
the lung transplant recipients tested, three primary infected patients had active, 
symptomatic HCMV infection, whereas of the eight seropositive transplant 
receptions, five had an active and partly subclinical infection. The two 
seropositive patients receiving a negative organ did not develop HCMV infection, 
suggesting that the infections in the former may be derived from the donor organ 
and therefore were defined as secondary infection. Local cytokine responses 
related to early rejection episodes might be responsible for triggering HCMV 
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reactivation in the transplanted organ (19). The time of the first detection of IE1 
and pp67 RNA by Qt NASBA in the lung transplant recipients is comparable to the 
qualitative findings by Blok et al. (2) and Gerna et al (9), as expected, since both 
qualitative and quantitative NASBA assays showed, comparable levels of 
sensitivity for in vitro RNA (9;Greijer et al, submitted). 
The mean time to detect a positive result for IE1 Qt NASBA in lung 
transplant recipients was 3.4 weeks, compared to 3.7 weeks in kidney transplants 
(2) and 5.4 weeks in bone marrow transplant recipients (9). The mean time of 
the first detection of pp67 RNA was at 4.1 weeks post-transplantation in primary 
infected patients and 5.8 weeks in transplant recipients with secondary 
infection, compared to 5.1 weeks in kidney transplant recipients and 6.2 weeks 
in bone marrow patients. The primary infections were detected at an earlier 
stage compared to patients with a secondary infection. The peak levels of RNA in 
100 l of blood of lung transplant recipients were log 6.6 molecules of IE1 RNA 
and log 5.6 molecules of pp67 RNA. 
In the blood of patients with an active HCMV infection, pp67 RNA levels are 
lower than IE1 RNA levels, which contrasts to the observation in infected HLF 
cells in vitro (log 4.7 copies of IE1 RNA and log 5.3 copies of pp67 RNA per 
infected cell) (Greijer et al., submitted). However, in vivo the HCMV RNA 
expression levels in circulating cells may be different from cultured cells and my 
differ for different cell types as well. Therefore it is important to note that 
levels in whole blood represent an averaged value of HCMV RNA expression. 
In addition, the higher levels of IE1 RNA may be explained by high numbers 
of cells with a restricted or abortive infection, expressing only immediate-early 
RNA without pp67 RNA expression, or by a difference in the mRNA expression 
ratios in blood leukocytes compared to HLF cells (10). 
When monitoring patients with antigenemia and IE1 and pp67 Qt NASBA, 
pp67 RNA was detected only in the highest peak of infection, during the period in 
which the antigenemia assay shows medium and high levels of positive cells. 
Immediate-early RNA was often present at levels up to 104 copies before 
positive antigenemia results are seen. After treatment with ganciclovir or 
foscarnet, pp67 levels decreased rapidly, whereas IE1 RNA remained detectable 
for longer periods. The prolonged detection of IE1 RNA reflects the limitation of 
current antiviral therapy, which interferes only with the late phase of the viral 
replication cycle, leaving the expression of IE1 unaffected. The final 
disappearance of IE1 RNA may indicate full immunological recovery and may 
suggest long-term control over HCMV infection. This, however, remains to be 
determined in subsequent studies. 
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Our results suggest that the dynamics of the IE1 RNA level are useful for 
monitoring disease progression. IE1 RNA levels up to 104 were detected in 
patients with subclinical HCMV infection, and rapidly increasing levels equal to or 
above 104 were related to disease development. pp67 RNA is detectable at a 
productive infection, though not detectable in the early phases of viral 
replication, when clinical symptoms are still absent. The number of pp67 RNA 
molecules did not relate to the number of pp65-positive cells in the antigenemia 
assay. This perception indicates that the presence and not the level of pp67 RNA 
is of prognostic value for antiviral drug management. However, it should be 
realized that antiviral treatment guided by early pp65 antigenemia may have 
influenced the pp67 mRNA levels detected in this study. The simultaneously pp67 
and IE1 mRNA levels by Qt NASBA could provide additional clinically relevant 
information on the biological activity and progression of HCMV infection in vivo. 
Especially in primary infected transplant recipients, initiation of antiviral therapy 
at the first activation of the virus would improve the outcome of HCMV infection, 
since the host‟s im m une system  m ight not be able to establish a rapid and 
appropriate response to HCMV. However, the early initiation of antiviral therapy 
may prevent appropriate antigen stimulation of the immune system, allowing 
relapse of HCMV replication upon cessation of treatment. On the other hand, the 
increase and decrease of IE1 RNA could give an indication of the extent to which 
the H C M V  infection is controlled by the host‟s im m une system . Therefore, the 
pp67 NASBA, indicating active replicating HCMV, in combination with a 
quantitative IE1 mRNA result might be preferred for optimal patient 
management. 
The results of this study indicate that combined testing for quantitative IE1 
RNA and qualitative pp67 RNA can recognize ongoing subclinical HCMV infection, 
allowing fine-tuning of the period of antiviral therapy to prevent progression to 
clinical significant HCMV infection. It is now possible to study the effect of 
treatment intended to prevent all HCMV activity, which may improve long-term 
allograft outcome. Since antigenemia results were used for guiding antiviral 
therapy, the clinical relevance of patient monitoring by IE1 Qt NASBA and 
qualitative pp67 needs to be determined by prognostic studies. 
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